Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnership with AstraZeneca, a ...

The AI system can detect a larger number of high-risk patients across France, Germany, Italy, Spain, and the UK by 2030.

The solution will use Owkin's data network and artificial intelligence to prescreen for gBRCA mutations in breast cancer directly from digital pathology slides.

Owkin has partnered with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer. Takeaway Points Owkin has ...

Alfa Laval will release third quarter earnings on 24 October at 07:30 am CET. The conference call will start at 09:00 am CET. The conference call is hosted by Alfa Laval's President and CEO Tom Erixon ...

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and ...

Owkin Inc. partnered with Astrazeneca plc to develop an artificial intelligence (AI)-powered tool to pre-screen for germline BRCA mutations (gBRCAm) in breast cancer directly from digitized pathology ...

Inn from the Cold will be announcing a major expansion of services aimed at providing enhanced support to vulnerable Calgary families, to now include expectant mothers. Full details will be revealed ...

The growth of AI in the healthcare sector is already having real-world impacts and promises a step-change in future care.

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca’s FASENRA ...

AstraZeneca’s FASENRA ® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1 EGPA is a rare, immune ...